Full Press Release Details
Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn
yield level demonstrates commercial viability; supports advancing to large-scale production
BC - April 26, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN),
a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol
("CBN"), today announced that its IntegraSyn cannabinoid manufacturing approach has achieved a level of 2g/L cannabinoid
yield, a milestone that signals commercial viability and supports advancement to large-scale production in the coming months.
its first application using the IntegraSyn approach, InMed set two main objectives to enable a cost-effective solution to cannabinoid
production: to achieve a commercially viable yield higher than current industry standards and to lower overall manufacturing costs through
process optimization. InMed's IntegraSyn manufacturing approach was able to achieve both objectives. IntegraSyn utilizes
an enzymatic biotransformation process as a part of an overall integrated cannabinoid manufacturing
approach to overcome certain natural yield limitations of traditional biosynthesis for full cannabinoid assembly. Having achieved
a 2g/L yield level, InMed will now focus on manufacturing scale-up to larger batch sizes while continuing process and enzyme optimization,
targeting increased cannabinoid yield and further reducing the overall cost of goods. In parallel, the Company continues to prepare the
manufacturing process to be Good Manufacturing Practice (GMP)-ready for pharmaceutical quality production. The next stage of large-scale
production is to produce a batch with a target output of one kilogram of the selected cannabinoid in 2H2021 via a GMP-ready process.
are very pleased to have achieved this high yield at this stage and are looking forward to applying the IntegraSyn approach to
large-scale production. As this scale-up progresses, we will also seek to further optimize our manufacturing and purification processes
and further enhance the enzyme design. These ongoing improvements will focus on achieving even higher yields, beyond the already impressive
2g/L," commented Eric Hsu, Senior Vice President, Preclinical R&D. "I would also like to acknowledge the Almac Group,
our collaborator and contract manufacturing partner, for bringing their extensive knowledge and expertise to the program as we reached
this important milestone."
Woudenberg, Vice President of Chemistry, Manufacturing and Controls, added, "In addition to achieving a commercially viable cannabinoid
yield level, we have focused on utilizing cost-competitive starting materials to enable a cost-effective solution to pharmaceutical-grade
cannabinoid production with IntegraSynTM. We believe this is especially important in accessing rare cannabinoids."
InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates,
initially focused on the therapeutic benefits of cannabinol ("CBN"), in diseases with high unmet medical need. The Company
is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For
more information, visit www.inmedpharma.com.
IntegraSyn : IntegraSyn is InMed's integrated cannabinoid manufacturing system designed to efficiently and economically
produce pharmaceutical-grade, bio-identical cannabinoids. The scalable and flexible IntegraSyn manufacturing system integrates
multiple commercially proven methods to efficiently produce cannabinoids utilizing cost-effective processes.
Almac Group: The Almac Group is an established contract development and manufacturing organization providing an extensive range
of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services
range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply,
Interactive Response Technology through to commercial-scale manufacture. Almac is an international, privately-owned organization which
has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe,
the US and Asia. For more information please visit almacgroup.com.
| Edison Group | ||
| Joe Green/Laine Yonker | ||
| T: +1.646.653.7030/+1.646.653.7035 | ||
| E: | jgreen@edisongroup.com | |
| lyonker@edisongroup.com |
Note Regarding Forward-Looking Information:
Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking
statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking
information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could
cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this
news release includes statements about: commercial viability and advancement to large-scale production and the timing thereof; the focus
of the Company on manufacturing scale-up to larger batch sizes while continuing process and enzyme optimization, targeting increased
cannabinoid yield and reducing overall costs; the preparation to be GMP-ready; IntegraSyn being able to efficiently and economically
produce pharmaceutical-grade, bio-identical cannabinoids; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs; and the next stage being a target output of one kilogram of the selected cannabinoid in 2H2021 via a GMP-ready
process. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding,
among other things: that the manufacturing approach means commercial viability and possible large-scale production; cannabinoid yield
can be increased; overall costs can be reduced; the manufacturing process is possible to be GMP-ready for pharmaceutical quality production;
and optimization of the manufacturing and purification processes and further enhancement of enzyme design is possible. While InMed considers
these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and
social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by the forward-looking information contained herein. Known risk factors include, among others: the outbreak and impact of COVID-19 may
worsen; commercial viability and large-scale production may not be possible within anticipated timelines or at all; the manufacturing
process may not be GMP-ready for pharmaceutical quality production; demand or interest for InMed's products may decrease or cease; and
economic and market conditions may become unstable or unfavorable. A more complete discussion of the risks and uncertainties facing InMed
is disclosed in InMed's filings with the Securities and Exchange Commission and the most recent Annual Information Form filed with
Canadian securities regulatory authorities on SEDAR at www.sedar.com. All forward-looking information herein is qualified in its entirety
by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly
announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or
developments, except as required by law.
THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY